Mizuho Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $45
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Mara Goldstein has initiated coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and set a price target of $45.
December 22, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Mara Goldstein initiated coverage on Syndax Pharmaceuticals with a Buy rating and a price target of $45.
Analyst coverage, especially with a Buy rating, tends to create positive sentiment around a stock. The price target of $45 suggests a significant upside potential from current levels, which can lead to increased investor interest and a potential short-term price increase for SNDX.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100